Does future technology in the delivery of stuff mean that this piece of kit will become obsolete?
http://www.news.com.au/technology/s...r-with-nanopatch/story-fn5fsgyc-1226106754530
Kennas everything becomes obsolete. However, in your average hospital intravenous injections are the only current way for delivering antibiotics/adrenaline etc in sufficient quantities. Add to that blood tests, radiological exams etc and needles are going to be around for a while.
Patches, when proved cheap, safe and effective may be useful for vaccines and targeted pain relief. The patches may in turn become obsolete by the use of food as a method of delivering vaccines.
http://www.adelaidenow.com.au/news/...r-barry-marshall/story-e6frea83-1226083776673
Shooting up on hype
January 17, 2004
Look sharp . . . Alan Shortall says his company, Unitract, is targeting a global market of $7 billion for its 'one-use' needles.
The chief executive has a chequered past. The biggest shareholder is elusive. Ben Hills investigates a company that claims it has found the Holy Grail.
Based on this 10c worth of plastic and metal, Shortall and his co-directors have built one of the hottest companies in the biotech sector, Unitract. Since listing more than a year ago the group's share price has rocketed 1000 per cent - giving it a capitalisation of around $200 million and putting it in the top 300 Australian companies. Its meteoric rise has prompted several queries from the Australian Stock Exchange.
By the end of March, he promises, 65 million of the retractable hypodermics will begin pouring off an imported assembly line in a sterile room at a factory at St Mary's in Sydney's west at the rate of two a second, and Unitract will be on its way to saving millions of lives around the world.
The hype from Shortall and his team for the past year, at closed-door presentations to investors and brokers and in media interviews,....
Investors have been told that the global market for syringes that Unitract is targeting is worth $7 billion a year,.....
The company has also received generous taxpayer funding - $240,000 from the Federal Government's Biotechnology Innovation Fund and $195,000 from two state government funds.
But Unitract has been less keen to highlight the hurdles it still faces in Australia,....
Shortall has been associated with three companies - one of them a listed high-tech company - which are now defunct.
Nor has the Herald been able to interview an elusive major investor who uses an address in London and who owns a quarter of the stock - worth some $42 million - through a company that is not registered in Australia or the UK.
Unitract's annual report tells the fairytale story of the invention of the syringe by two Hunter Valley tool and die makers, Craig Thorley and his boss at Argo Engineering in Morpeth, Joe Kaal....
Thorley did confirm, however, that he and Kaal had spent five years developing the prototype syringe - in between making parts for motor-boat gearboxes at Argo Engineering on $500 a week.
"I have slaved my backside off, and now I am living the dream," Thorley says. "It's all going to happen."
Savvy stockmarket operators, however, have not been as enthusiastic....
A Melbourne analyst was also unimpressed by a presentation where Shortall extolled the virtues of Unitract's product compared with rival syringes he brought back from a conference in Phnom Penh, Cambodia.
"He's unusual-looking, bald as a billiard-ball, a big man who presents well - perhaps too well ...."
Shortall says Unitract has patents in the US and Australia. But the syringe does not yet have approval from the Therapeutic Goods Administration (TGA) in Canberra, essential before it can be sold. Shortall says such approval can be granted only after manufacture actually begins....
Then there is the issue of Shortall's business background.
Thorley says he did not check his partner's past, and that he contacted Shortall for help in commercialising his invention through his involvement in a charity called the Mankind Project (MKP).
Shortall concedes that this is not a registered charity, but a men's organisation which he supports, "the essence of which is around supporting men in the community, around integrity, accountability, love, compassion and congruence".
Shortall refuses to go into any more detail, but MKP's US website says it runs "New Warrior weekends" at which, for $US600 ($780), men can become "initiated", discovering "highly focused aggressive energy that empowers and shapes the inner masculine self . . . the New Warrior is at once tough and loving, wild and gentle, fierce and tolerant".
Unusually for a chief executive these days - when even the office boy seems to have an MBA - Shortall has no tertiary qualification....
Perth was also where, according to Australian Securities and Investments Commission records, he set up one of three defunct companies with which he has been associated, ....
His name first appears in West Australian papers two years later, this time in connection with a much more ambitious enterprise - Formulab Neuronetics....
In fact Formulab was the invention of Adelaide-born long-haired eccentric and self-styled genius Anthony Richter. Like Unitract, it was backdoor listed on the ASX in 1995, claiming to have a revolutionary new invention.
There the comparisons end. Richter's invention was far more complicated than a humble syringe. He claimed his "Richter Paradigm" was a "thinking computer" -.....
Richter's big mistake was taking the "brain in a shoebox," as it was dubbed, to the US. When he demonstrated it to American investors, they ridiculed the gadget and the share price collapsed to 67c.....
Shortall says he was hired to get the company listed on the Nasdaq high-tech board in the US, which he did. Despite being quoted as company spokesman in the media, and being employed as Richter's "executive assistant", he says he only worked for Formulab for seven months,....
Nevertheless, within three years of leaving Formulab, Shortall was in charge of a third company, this time from his new base on Queensland's Gold Coast. The company, Sigma Global Pty Ltd, sold "investment analysis software," which Shortall reluctantly explains was designed to help people pick winners at horse races.
Asked whether his involvement in these three companies constituted an "exceptional track record" and "successful marketing", as claimed in his corporate CV, Shortall says: "I think you are being very unfair. I think you are being extremely unfair."
Since Unitract was floated, Shortall has been leading a ritzy lifestyle, occupying a mansion in beachside Tamarama which rents for $14,000 a month, has two Mercedes cars and a Bentley (which he says is for sale),....
His annual pay of $396,726 in cash and share options is paid to Underline International Pty Ltd, a company that provides Shortall's services to Unitract. Shortall says he receives only "about $15,000 a month" from Underline, which leaves the company more than $200,000 a year in front.
Shortall owns only four of the 100 shares in Underline, with 95 shares being held by a Unitract investor called Roger Williamson who gives a London address...
Why this convoluted arrangement? Shortall offers no explanation beyond saying that "there's nothing dodgy or sinister about it". He says Williamson pays the rent on the house because he sometimes stays there when he is visiting Australia.
But the Unitract board believes all this is insufficient reward for Shortall's talents. At the company's recent annual meeting they intended to propose the issue of 8.5 million options to Shortall over the next 2 years,....
All up, he would get 12.5 million shares for nothing but his hard work, making him the company's second biggest shareholder with a stake worth around $27 million - more than the entire amount Unitract has raised since it floated....
With additional research by Emiliya Mychasuk in London.
October 5, 2011
Unilife Wins Supply Contract with Nation's Largest Healthcare Alliance
Premier Selects Unitract ® 1mL Safety Syringes for Two-Year Contract
YORK, P.A., Oct. 5, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced it has been awarded a two-year contract by Premier Purchasing Partners, L.P., the group purchasing enterprise of the Premier healthcare alliance, for the supply of its Unitract ® 1mL safety syringes.
Premier, Inc. is the nation's largest healthcare alliance, helping to improve performance and providing group contracting to more than 2,500 U.S. hospitals and over 76,000 healthcare sites nationwide.
July 19, 2011
Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
YORK, Pa., July 19, 2011 /PRNewswire/ --
Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced it has commenced the initial sale of the Unifill ® ready-to-fill syringe to a U.S.-based global pharmaceutical company.
The commencement of Unifill sales to this new customer, whose identity remains confidential at this time, follows the initial shipment of the device to Sanofi last week. Unilife continues to expand its customer pipeline as an increasing number of pharmaceutical companies seek access to Unifill for the delivery of their prefilled injectable drugs.
Unilife expects this new U.S.-based pharmaceutical customer to conduct drug compatibility and stability tests with their injectable drugs in combination with Unifill as per standard industry practices for drug-device combination products. The resulting data is then filed to regulatory agencies as a final step before approval.
Jefferies have bought 4,995,364 of the 8,250,000 sold. huh? The underwriter has bought over half the raising and Alan has bought 4,028,768 shares as part of Jerreries.UNILIFE CORPORATION ANNOUNCES PRICING OF OFFERING OF 8,250,000 SHARES OF COMMON STOCK
York, PA, November 17, 2011- Unilife Corporation (NASDAQ: UNIS / ASX: UNS) (“Unilife” or the “Company”) today announced the pricing of its underwritten registered public offering of 8,250,000 shares of common stock at a public offering price of $4.35 per share. All of the shares in the offering are to be sold by Unilife. In connection with the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock to cover over-allotments, if any.
The net proceeds of the offering to the Company, after deducting the underwriting discount and estimated offering expenses, are expected to be approximately $33,808,125, exclusive of any proceeds attributable to the underwriters’ possible exercise of their over-allotment option. Unilife expects to use the net proceeds from this offering to fund the continued development and commercial supply of its diversified portfolio of advanced drug delivery systems, the expansion of its workforce to support anticipated customer demands, and for working capital and other general corporate purposes. The offering is expected to close on November 21, 2011 and is subject to customary closing conditions.
What does this mean? Have they 'sold' anything yet?We commenced initial production and supply of the Unifill syringe to Sanofi and one other U.S. based pharmaceutical company in July 2011.
Seems I've scared off the UNS bandwagon by asking questions ..
Now, next on the dodgy deals agenda is the capital raising. For some time they've been saying that they're doing great, wonderful, sales full steam ahead and then they go to the market for a pile of cash. Can anyone explain the nature of this raising?
Also, the underwriting announcement? Jefferies and Co now own 8% of the company. Alan seems to have quite a stake in Jefferies. Like most of it. huh?
Jefferies have bought 4,995,364 of the 8,250,000 sold. huh? The underwriter has bought over half the raising and Alan has bought 4,028,768 shares as part of Jerreries.
Sounds like they've done this raising to hire extra people 'just in case' they actually sell any of their bits and to keep paying their current exorbitant management salaries.
Just what was the 'underwriters discount'? 21c a share. On top of the discount at the last sale price in the US. I can only find that the stock was trading at $4.75, the offer was at $4.35 and then they got 0.21c off that as well.
So, if Alan has bought 4,028,768 shares @ $4.14 = $16.7m ish. HUH?Where did he get the money to do that?
They claim that they started to 'supply' their syringes in July 2011.
What does this mean? Have they 'sold' anything yet?
Do they have any accounts recording sales at all?
I dug into this and it was mentioned in the pre pre-AGM meetings that shareholders had to agree to certain things that resulted in the issue of shares. I tried to look through the detail in the fine print but really couldn't find where he had succeeded in achieving the performance hurdles.Does anyone know why Alan got 1.9m in shares approved issued at the last AGM?
November 29, 2011
Unilife Signs Clinical Development and Supply Agreement with Global Pharmaceutical Company
YORK, Pa., Nov. 29, 2011 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS; ASX: UNS) today announced the signing of a clinical development and supply agreement with a global pharmaceutical company for a novel device for targeted organ delivery. The proprietary Unilife device is intended to be used in a drug clinical trial that is scheduled to commence in early 2012.
The terms of the agreement and the pharmaceutical company are to remain confidential at this time. Unilife will receive $1.4 million in development fees and revenue from initial unit sales of the devices for the clinical trial under the first phase of this program. Upcoming phases of the clinical development program are expected to generate additional revenues for Unilife over the coming year.
Alan's shares were issued to him a could of days ago. $550K worth for meeting his performance hurdles which were basically 'do your job'. I find it quite troubling that a company not making any money with zero sales can give it's managers such heafty base salaries and then these huge incentive bonus'. His salary is about $400K I think so he's earning about $1m. Incredible.I dug into this and it was mentioned in the pre pre-AGM meetings that shareholders had to agree to certain things that resulted in the issue of shares. I tried to look through the detail in the fine print but really couldn't find where he had succeeded in achieving the performance hurdles.
Can any one else quote why he was issued these shares?
One interesting thing regarding the remuneration of Directors is the benchmarking that was conducted by the 'independent' consultants. The other 15 or so companies had MCs of 200m or so with quite significant cash flow. UNS has a MC of about the same with negative cash flow. That is, the only money they are getting in is via cap raisings, grants and tax losses. They are not only earning NOTHING from sales, but losing from every direction.
Just what happened to this significant announcement?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?